Bayer Q3 sales, EBITDA beat estimates; raises 2026 earnings and cash flow outlook
Published . Updated .
Covered by 2 outlets: Yahoo Finance, Investing.com.
Who covered it: Center 2. How we rate outlets
Investing.com -- Bayer (ETR:BAYGn) raised its full-year earnings and cash flow forecasts on Tuesday after third-quarter sales and EBITDA beat analyst expectations, driven by strong growth in its pharmaceuticals division.
Directly affected
- BAYRY Bayer (ETR: BAYN)
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
A fund of health-care companies. Linked by “sector of BAYRY” in this story
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BAYRYNon-US listing (OTC); price checks may stay empty | — | — | — | — | — | — | — |
| XLV | -2.95% | -0.31% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Bayer Q3 sales, EBITDA beat estimates; raises 2026 earnings and cash flow outlook Yahoo Finance Singapore
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
This story
25 out of 100
“Bayer Q3 sales, EBITDA beat estimates; raises 2026 earnings and cash flow outlook” scores 25 out of 100. The score uses 2 sources.